PRODUCTS & SERVICES
CUSTOM OLIGO SYNTHESISRNA SEQUENCINGFLUORESCENT IN SITU HYBRIDIZATIONPERSONALIZED DIAGNOSTICS
Project title: Education in Modern Trends in Oncological Diagnostics
Funding Scheme: Operational Program Human Resources
Starting date: 01/11/2018
Duration in months: 22
Estimated budget: € 186 038,00
The aim of the project is to acquire the necessary theoretical knowledge and practical skills in the field of modern and personalized diagnostics of oncological diseases. Modern trends in oncological diagnostics are evolving rapidly, but education often lags behind these trends. Many diagnostic technologies that are currently being put into practice or in development (e.g., the diagnostic methods that we develop within our company MultiplexDX) are difficult to include into the educational process. Medical and science students, and often practicing oncologists, are unable to obtain information about state-of-the-art diagnostic methods. In addition, the development of novel diagnostics is based on the latest advancements of genomics, proteomics, metabolomics, and bioinformatics, areas that are challenging to comprehend through self-study. Therefore, even experts have difficulty navigating modern trends and recognizing the strengths or weaknesses of modern diagnostic technologies and their applications. Together with our team of expert advisors, we will conduct an in-depth analysis of innovative diagnostic technologies and create a modern and interactive training for oncologists, medical and science students, and their teachers in molecular pathology, molecular biology, diagnostics, clinical oncology, clinical biochemistry and histology. Using an educational tutorial, we plan to educate this target group of students and experts about the origins of cancer, the importance of biomarkers in tumour recognition, the basics of biomarker quantification in proper personalized diagnosis and treatment of tumours, analysis and comparison of diagnostic technologies, use of diagnostic methods in practice, etc. This project is supported by the European Social Fund and the European Regional Development Fund under the Operational Program Human Resources. Managing authority: Ministry of Labour, Social Affairs and Family.
MultiplexDX is one of the most innovative biotech corporations, created to bring its revolutionary technologies to the market of personalized molecular diagnostics. The company has representation in both U.S. and European markets. The collaborators of MultiplexDX are from the world’s most prestigious scientific organizations including the National Cancer Institute, Rockefeller University, Albert Einstein University, Vanderbilt University, Cornell University, Queens University (Canada), Hebrew University of Jerusalem (Israel), and the Max Delbrück Center for Molecular Medicine (Germany).
MultiplexDX IP-based and innovative platform merges histopathology methods, biomarker quantification, visualization and gene expression with a single-cell resolution by combining MDX proprietary visual and sequencing technologies into one diagnostic test. This cross-validation approach eliminates diagnostic errors and creates 100% precise cancer profiling for each patient which allows clinicians to suggest specific, personalized cancer treatment.